Biotech: Page 21
-
Daniel Tadevosyan via Getty Images
Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance
Zealand is using a recent $1 billion equity raise to “accelerate” several would-be weight loss medicines. Meanwhile, Bluebird reworked a loan and Boundless Bio cut jobs only months after an IPO.
By BioPharma Dive staff • Aug. 16, 2024 -
Makhbubakhon Ismatova via Getty Images
Lykos to cut 75% of staff after FDA rejection of MDMA-based therapy
The layoffs are part of a larger reorganization that will also see the departure of Lykos’ founder, the psychedelics advocate Rick Doblin.
By Jacob Bell • Aug. 15, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.
By BioPharma Dive staff -
Courtesy of Grail
Grail to shed 350 workers in restructuring
Less than two months after splitting from Illumina, the liquid biopsy maker is refocusing resources as it pursues an FDA submission for the Galleri multi-cancer early detection test.
By Susan Kelly • Aug. 14, 2024 -
cagkansayin via Getty Images
Acelyrin shifts from main drug, lays off staff
The company will no longer develop its medicine izokibep in two immune conditions, prioritizing another treatment it’s developing for thyroid eye disease.
By Ned Pagliarulo • Aug. 13, 2024 -
Sarah Silbiger via Getty Images
Galderma wins FDA approval for skin condition treatment
Nemluvio is now cleared for adults with the chronic itching condition prurigo nodularis, making it a competitor to Sanofi and Regeneron’s Dupixent.
By Ned Pagliarulo • Updated Aug. 13, 2024 -
Daniel Tadevosyan via Getty Images
Lilly opens R&D hub; Ovid and Lexicon lay off staff
Lilly’s new center in Boston will focus on genetic medicine research and provide lab space for startups. Elsewhere, two biotechs cut jobs and two others advanced psychedelic medicines.
By BioPharma Dive staff • Aug. 13, 2024 -
Dr_Microbe via Getty Images
Startup Halda raises $126M to advance new type of targeted cancer therapy
Technology inspired by work at Yale researcher Craig Crews’ labs will be used to target prostate and breast cancer in early clinical trials.
By Jonathan Gardner • Updated Aug. 13, 2024 -
Sarah Silbiger via Getty Images
FDA approves Ascendis drug for rare endocrine condition
The clearance of Yorvipath for hypoparathyroidism was some time coming for Ascendis, which had resubmitted after receiving a rejection last year.
By Ned Pagliarulo • Aug. 12, 2024 -
Newbird via Getty Images
Emerging biotechWith pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
Recent data from J.P. Morgan indicates early-stage startups are getting smaller upfront payments in alliances than a few years ago, a trend industry insiders attribute to weaker leverage in deal talks.
By Gwendolyn Wu • Aug. 9, 2024 -
Daniel Tadevosyan via Getty Images
Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study
Merck stopped a Phase 3 TIGIT study for futility. Elsewhere, shares in Cabaletta Bio sank on safety worries and Vertex secured Casgevy reimbursement in England.
By BioPharma Dive staff • Aug. 8, 2024 -
Courtesy of Apellis Pharmaceuticals
Apellis plans FDA filing after drug success in kidney trial
Analysts at Evercore ISI called pegcetacoplan’s data in two kidney conditions a “left-field hit” that compare favorably to results for a Novartis treatment.
By Ned Pagliarulo • Aug. 8, 2024 -
Daniel Tadevosyan via Getty Images
Amgen talks obesity drug ‘differentiation’; Servier brain cancer drug approved by FDA
Executives at Amgen had few updates on their drug MariTide, but defended what they see as the once-monthly shot’s competitive profile.
By BioPharma Dive staff • Aug. 7, 2024 -
Courtesy of Madrigal Pharmaceuticals
Madrigal’s MASH drug launch gets off to a fast start
U.S. sales of the medicine, Rezdiffra, were more than triple analysts’ expectations, encouraging Madrigal to market it in Europe without a partner.
By Ben Fidler • Aug. 7, 2024 -
Courtesy of Roche
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
By Jacob Bell • Aug. 6, 2024 -
Honglouwawa via Getty Images
Biotech entrepreneur Arie Belldegrun launches new ‘science-first’ credit firm
Symbiotic Capital, which has $600 million in committed capital, aims to make credit a more accessible tool for life sciences companies.
By Delilah Alvarado • Aug. 6, 2024 -
Courtesy of BioMarin Pharmaceutical
BioMarin pares Roctavian spending as it narrows sales focus
The company plans to limit sales of the hemophilia gene therapy to the U.S., Italy and Germany, while ending most clinical development work.
By Ned Pagliarulo • Aug. 6, 2024 -
Permission granted by Red Queen Therapeutics
Biotech Red Queen launches with $55M to build versatile antivirals
The funding from Apple Tree Partners will help the startup advance an antiviral drug pipeline that includes a COVID treatment nearing mid-stage testing.
By Delilah Alvarado • Aug. 6, 2024 -
Courtesy of 23andMe
23andMe board rejects CEO Wojcicki’s take-private proposal
A special committee of the board said the proposal offers no premium to 23andMe’s stock price and, with a lack of committed financing, is “insufficient.”
By Elise Reuter • Aug. 2, 2024 -
Daniel Tadevosyan via Getty Images
Vir retreats from infectious disease; Vertex shelves AATD drugs
The one-time drug developer is pivoting to cancer research. Elsewhere, Neurocrine reported a strong quarter and venBio raised half a billion dollars for biotech investing.
By BioPharma Dive staff • Aug. 2, 2024 -
Courtesy of UniQure
UniQure restructuring to claim 300 jobs
The job cuts affect 65% of UniQure’s workforce and include the gene therapy developer’s recent sale of a manufacturing plant to Genezen.
By Delilah Alvarado • Aug. 1, 2024 -
Elizabeth Regan/BioPharma Dive
Otsuka buys startup Jnana, adding to uptick in private biotech M&A
The $800 million deal hands Otsuka a drug that’s shown promise in early testing in phenylketonuria, and is the fourth buyout of a privately held biotech in the last two weeks alone.
By Kristin Jensen • Aug. 1, 2024 -
Daniel Tadevosyan via Getty Images
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
Quarterly sales of Merck’s immunotherapy crested $7 billion for the first time. Elsewhere, Fibrogen is laying off staff and Intellia has a green light to start a new gene editing trial in the U.K.
By BioPharma Dive staff • July 31, 2024 -
Permission granted by AIRNA
Biotech startup Airna raises $60M for RNA editing medicines
Launched last September, the company is working on a treatment for alpha-1 antitrypsin deficiency, which it said could enter the clinic in 2025.
By Gwendolyn Wu • July 31, 2024 -
Permission granted by Incyte
Incyte trims cancer drug pipeline in R&D refocus
The company will stop developing five experimental treatments, including two oral checkpoint inhibitors targeting PD-L1.
By Ned Pagliarulo • July 30, 2024 -
Permission granted by Mubadala Capital
Q&AHow a Mubadala partner views investing in biotech’s new normal
Ayman AlAbdallah discusses some of the inroads the sector has made toward a recovery and the characteristics he looks for in a startup.
By Meagan Parrish • July 29, 2024
Previous
